The Oncology Institute, Inc.
TOI
$4.59
$0.122.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 545.76M | 502.73M | 461.04M | 424.38M | 403.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 545.76M | 502.73M | 461.04M | 424.38M | 403.15M |
| Cost of Revenue | 463.26M | 426.29M | 392.73M | 360.62M | 343.88M |
| Gross Profit | 82.50M | 76.44M | 68.31M | 63.75M | 59.28M |
| SG&A Expenses | 108.41M | 105.57M | 102.39M | 103.79M | 104.75M |
| Depreciation & Amortization | 6.78M | 6.94M | 7.02M | 6.87M | 6.58M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 578.45M | 538.81M | 502.14M | 471.28M | 455.21M |
| Operating Income | -32.69M | -36.08M | -41.11M | -46.90M | -52.06M |
| Income Before Tax | -43.64M | -60.74M | -66.41M | -66.02M | -64.36M |
| Income Tax Expenses | -131.00K | -131.00K | -131.00K | -131.00K | -- |
| Earnings from Continuing Operations | -43.51 | -60.61 | -66.28 | -65.89 | -64.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.51M | -60.61M | -66.28M | -65.89M | -64.36M |
| EBIT | -32.69M | -36.08M | -41.11M | -46.90M | -52.06M |
| EBITDA | -25.91M | -29.14M | -34.09M | -40.04M | -45.48M |
| EPS Basic | -0.38 | -0.56 | -0.64 | -0.68 | -0.70 |
| Normalized Basic EPS | -0.28 | -0.40 | -0.46 | -0.49 | -0.50 |
| EPS Diluted | -0.38 | -0.57 | -0.65 | -0.69 | -0.71 |
| Normalized Diluted EPS | -0.28 | -0.40 | -0.46 | -0.49 | -0.50 |
| Average Basic Shares Outstanding | 393.94M | 369.23M | 343.43M | 321.48M | 303.03M |
| Average Diluted Shares Outstanding | 393.94M | 369.23M | 343.43M | 321.48M | 303.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |